Bipolar Disorder

Brilaroxazine, a potential new treatment for schizophrenia, significantly improved symptoms and was well-tolerated in a pivotal phase 3 trial, according to a press release from its manufacturer.

An earlier follow-up visit after psychiatric inpatient discharge was associated with lower risk of suicide in a population-based study from South Korea.

Mental health conditions affect one in eight people and one in seven adolescents worldwide, according to WHO.

A potential new lithium treatment for bipolar disorder, designed to avoid toxicities currently associated with the substance, is set to undergo a phase 2 study.

Factors previously associated with short-term risk for new-onset bipolar disorder also were associated with significantly higher risk after more than 10 years of follow-up, according to a study published in JAMA Network Open.

A clinical-stage biopharmaceutical company has announced the submission of an investigational new drug application to the FDA based upon results of a phase 2a clinical study of a novel lithium delivery system, AL001, for bipolar disorder.

Subcallosal cingulate gyrus deep brain stimulation was generally safe and significantly improved depressive symptoms in patients with treatment-resistant depression, with results sustained up to 7 years, according to research.

BOSTON — With a multitude of products spanning neuroscience and psychiatry, executives at AbbVie say they are committed to learning the full clinical value of all of the company’s products for the benefit of patients.

Symptom dimensions within bipolar disorder may have distinct causes, supporting the hypothesis that genetic heterogeneity underpins clinical heterogeneity, according to a study published in The Lancet Psychiatry.

WASHINGTON — In this video, Natasha Bowman, JD, SPHR, keynote speaker at the Digital Therapeutics Alliance Summit, shares tips for reducing burnout among physicians.